250 related articles for article (PubMed ID: 28204912)
1. Effect of food on the bioavailability of palbociclib.
Ruiz-Garcia A; Plotka A; O'Gorman M; Wang DD
Cancer Chemother Pharmacol; 2017 Mar; 79(3):527-533. PubMed ID: 28204912
[TBL] [Abstract][Full Text] [Related]
2. Effect of a high-fat meal on the relative bioavailability of H3B-6527, a novel FGFR4 inhibitor, in healthy volunteers.
Rioux N; Kim A; Nix D; Bowser T; Warmuth M; Smith PG; Schindler J
Cancer Chemother Pharmacol; 2019 Jan; 83(1):91-96. PubMed ID: 30368584
[TBL] [Abstract][Full Text] [Related]
3. Impact of Acid-Reducing Agents on the Pharmacokinetics of Palbociclib, a Weak Base With pH-Dependent Solubility, With Different Food Intake Conditions.
Sun W; Klamerus KJ; Yuhas LM; Pawlak S; Plotka A; O'Gorman M; Kirkovsky L; Kosa M; Wang D
Clin Pharmacol Drug Dev; 2017 Nov; 6(6):614-626. PubMed ID: 28430398
[TBL] [Abstract][Full Text] [Related]
4. Physiologically Based Pharmacokinetic Modeling of Palbociclib.
Yu Y; Loi CM; Hoffman J; Wang D
J Clin Pharmacol; 2017 Feb; 57(2):173-184. PubMed ID: 27402157
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients.
Tamura K; Mukai H; Naito Y; Yonemori K; Kodaira M; Tanabe Y; Yamamoto N; Osera S; Sasaki M; Mori Y; Hashigaki S; Nagasawa T; Umeyama Y; Yoshino T
Cancer Sci; 2016 Jun; 107(6):755-63. PubMed ID: 26991823
[TBL] [Abstract][Full Text] [Related]
6. Effects of food on the pharmacokinetics of ponatinib in healthy subjects.
Narasimhan NI; Dorer DJ; Niland K; Haluska F; Sonnichsen D
J Clin Pharm Ther; 2013 Dec; 38(6):440-4. PubMed ID: 23888935
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach.
Sun W; O'Dwyer PJ; Finn RS; Ruiz-Garcia A; Shapiro GI; Schwartz GK; DeMichele A; Wang D
J Clin Pharmacol; 2017 Sep; 57(9):1159-1173. PubMed ID: 28419480
[TBL] [Abstract][Full Text] [Related]
8. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
[TBL] [Abstract][Full Text] [Related]
9. Palbociclib (PD-0332991) pharmacokinetics in subjects with impaired renal function.
Yu Y; Hoffman J; Plotka A; O'Gorman M; Shi H; Wang D
Cancer Chemother Pharmacol; 2020 Dec; 86(6):701-710. PubMed ID: 33037918
[TBL] [Abstract][Full Text] [Related]
10. Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three phase I, single-dose crossover studies in healthy volunteers.
Derks M; Kawamura H; Abt M; Meneses-Lorente G; Phelan M; Ishikawa T
Clin Ther; 2011 Jun; 33(6):754-65. PubMed ID: 21704240
[TBL] [Abstract][Full Text] [Related]
11. The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial.
Gandelman K; Alderman JA; Glue P; Lombardo I; LaBadie RR; Versavel M; Preskorn SH
J Clin Psychiatry; 2009 Jan; 70(1):58-62. PubMed ID: 19026256
[TBL] [Abstract][Full Text] [Related]
12. A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects.
Graefe-Mody U; Giessmann T; Ring A; Iovino M; Woerle HJ
Clin Ther; 2011 Aug; 33(8):1096-103. PubMed ID: 21803422
[TBL] [Abstract][Full Text] [Related]
13. A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects.
Crockett J; Critchley D; Tayo B; Berwaerts J; Morrison G
Epilepsia; 2020 Feb; 61(2):267-277. PubMed ID: 32012251
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects.
Tomkinson H; McBride E; Martin P; Lisbon E; Dymond AW; Cantarini M; So K; Holt D
Clin Ther; 2017 Nov; 39(11):2260-2275.e1. PubMed ID: 28985960
[TBL] [Abstract][Full Text] [Related]
15. Food effects on the pharmacokinetics of doxylamine hydrogen succinate 25 mg film-coated tablets: a single-dose, randomized, two-period crossover study in healthy volunteers.
Videla S; Lahjou M; Guibord P; Xu Z; Tolrà C; Encina G; Sicard E; Sans A
Drugs R D; 2012 Dec; 12(4):217-25. PubMed ID: 23230999
[TBL] [Abstract][Full Text] [Related]
16. A Phase I, Randomized, Crossover, Open-label Study of the Pharmacokinetics of Solriamfetol (JZP-110) in Healthy Adult Subjects With and Without Food.
Zomorodi K; Kankam M; Lu Y
Clin Ther; 2019 Feb; 41(2):196-204. PubMed ID: 30598342
[TBL] [Abstract][Full Text] [Related]
17. Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast Cancer.
Molenaar-Kuijsten L; Braal CL; Groenland SL; de Vries N; Rosing H; Beijnen JH; Koolen SLW; Vulink AJE; van Dongen MGJ; Mathijssen RHJ; Huitema ADR; Steeghs N;
Clin Pharmacol Ther; 2022 Feb; 111(2):477-484. PubMed ID: 34674222
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC-042).
Van Mater D; Gururangan S; Becher O; Campagne O; Leary S; Phillips JJ; Huang J; Lin T; Poussaint TY; Goldman S; Baxter P; Dhall G; Robinson G; DeWire-Schottmiller M; Hwang EI; Stewart CF; Onar-Thomas A; Dunkel IJ; Fouladi M
Pediatr Blood Cancer; 2021 Apr; 68(4):e28879. PubMed ID: 33405376
[TBL] [Abstract][Full Text] [Related]
19. Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPARαγ Agonist, in Healthy Adult Subjects.
Patel MR; Kansagra KA; Parikh DP; Parmar DV; Patel HB; Soni MM; Patil US; Patel HV; Patel JA; Gujarathi SS; Parmar KV; Srinivas NR
Clin Drug Investig; 2018 Jan; 38(1):57-65. PubMed ID: 29022212
[TBL] [Abstract][Full Text] [Related]
20. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
